Drugs / A0001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01074359 | Feb → Nov 2010 | neuromuscular disease | Penwest Pharmaceuticals Co. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A0001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01074359 ↗ |
| Known as | alpha-tocopherolquinone | “Drug: A0001 (alpha-tocopherolquinone)” NCT01074359 ↗ |
| Route | Oral | “28 days (1.5 g total daily dose) oral A0001 capsules.” NCT01074359 ↗ |